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ABSTRACT: Objective: Minocycline rescued synaptic abnormalities and improved behavior in the fragile X
mouse model. Previous open-label human studies demonstrated benefits in individuals with fragile X syn-
drome (FXS); however, its efficacy in patients with FXS has not been assessed in a controlled trial. Method:
Randomized, double-blind, placebo-controlled, crossover trial in individuals with FXS, aged 3.5 years to 16
years (n 5 55, mean age 9.2 [SD, 3.6] years). Participants were randomized to minocycline or placebo for 3
months and then switched to the other treatment. Results: Sixty-nine subjects were screened and 66 were
randomized. Fifty-five subjects (83.3%) completed at least the first period and 48 (72.7%) completed the full
trial. Intention-to-treat analysis demonstrated significantly greater improvements in one primary outcome,
Clinical Global Impression Scale—Improvement after minocycline compared with placebo (2.49 6 0.13 and
2.976 0.13, respectively, p5 .0173) and greater improvement in ad hoc analysis of anxiety and mood-related
behaviors on the Visual Analog Scale (minocycline: 5.26 cm 6 0.46 cm, placebo: 4.05 cm 6 0.46 cm;
p 5 .0488). Side effects were not significantly different during the minocycline and placebo treatments.
No serious adverse events occurred on minocycline. Results may be potentially biased by study design
weaknesses, including unblinding of subjects when they completed the study, drug-related side effects
unblinding, and preliminary efficacy analysis results known to investigators. Conclusions: Minocycline
treatment for 3 months in children with FXS resulted in greater global improvement than placebo. Treatment
for 3 months appears safe; however, longer trials are indicated to further assess benefits, side effects, and
factors associated with a clinical response to minocycline.
(J Dev Behav Pediatr 34:147–155, 2013) Index terms: fragile X syndrome, intellectual disability, minocycline, matrix metalloproteinase 9.
Fragile X syndrome (FXS) is the most common
inherited cause of intellectual disability and the most
common single gene cause of autism. Prevalence esti-
mates are 1 in ;4000 to 8000; however, the full muta-
tion allele frequency may be as high as 1 in ;2500 in
some populations.1,2 The phenotype associated with FXS
includes both behavioral and cognitive deficits in addi-
tion to physical features, such as prominent ears,
hyperextensible finger joints, and macroorchidism,
which begins at puberty. The behavioral phenotype
typically includes attention-deficit hyperactivity disorder
(ADHD), anxiety and intermittent aggression, which can
cause significant difficulties for the families.
FXS is almost always caused by a CGG repeat
expansion in the 59 region of the FMR1 gene on the X
chromosome. Greater than 200 CGG repeats confer the
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full mutation, leading to silencing of the gene
and a deficit of the gene’s product, fragile X mental
retardation protein (FMRP). The FMRP is a key regulator
of translation of many messenger RNAs into their spe-
cific proteins, so that the deficiency of FMRP leads to
upregulation of many proteins important for synaptic
plasticity.3–5
The lack of FMRP in individuals with FXS leads to
upregulation of downstream components of the metabo-
tropic glutamate receptor (mGluR) 5 pathways.6 For fur-
ther discussion of this, please refer to Dolen et al.7 The
mGluR5 negative modulators represent the first targeted
treatment for FXS and have been found to be helpful in
animal models of FXS.8 In individuals with FXS, mGluR5
antagonists, including fenobam and AFQ056, have shown
preliminary evidence of efficacy in initial studies.9,10
Lithium is also a targeted treatment for FXS as it decreases
mGluR5 activated translation and was found to be effica-
cious in an open-label trial in individuals with FXS.11
Another potential pathway that may be targeted in the
treatment of FXS is the gamma-aminobutyric acid (GABA)
system, which is downregulated in FXS, and in a recent
randomized-controlled phase II trial, treatment with
arbaclofen, a GABA type B agonist, led to improvements
in social avoidance and behavior in individuals with FXS
but is not yet available for prescription.12
The lack of FMRP in individuals with FXS is also asso-
ciated with alterations in the expression of a number of
proteins, including matrix metalloproteinase (MMP) 9.13
Matrix metalloproteinases are endopeptidases (please see
Sternlicht and Werb14 for further discussion of their role
in the cell), and MMP9 has been found to be fundamental
in modulating hippocampal synaptic physiology and
plasticity.15 In the Fmr1 knock out (KO) mouse model for
FXS, MMP9 levels were found to be elevated in the hip-
pocampus and lowered by minocycline treatment.13
Minocycline is a semisynthetic tetracycline derivative
that has been available since the 1970s, and its poten-
tial as a neuroprotective agent was first investigated by
Yrjanheikki et al16 as a possible treatment for cerebral
ischemia. Bilousova et al13 found that early treatment with
minocycline (,4 weeks) after birth led to maturation of
the immature dendritic spines found in the Fmr1 KO
mice, suggesting that dendritic maturation may be related
to minocycline’s lowering of MMP9. Improvements in
anxiety and cognition were also seen in the treated
mice.13 In the Drosophila model of FXS, overexpression
of the only tissue inhibitor of MMPs, tissue inhibitor of
metalloproteinase, prevented the synaptic defects seen in
the dfmr1 mutants and minocycline treatment was found
to normalize synaptic structure.17 Minocycline treatment
was also found to normalize ultrasonic vocalizations of
Fmr1 KO mice during mating.18
Minocycline is not only a common treatment for
multiple conditions including acne vulgaris and infectious
diseases, such as rocky mountain spotted fever, but has
also been found to have neuroprotective effects.19 It has
a well-defined side effect profile including gastrointestinal
problems ranging from stomach upset to the rare possi-
bility of pseudomembranous colitis, tooth and oral cavity
discoloration, a lupus-like syndrome, increased photo-
sensitivity, pseudotumor cerebri, and autoimmune
hepatitis.20 Because of the possibility of graying of the
permanent teeth, minocycline is generally not recom-
mended in children aged younger than 8 years (as min-
eralization of the teeth is not complete until after that
age), unless there are no other medications that are likely
to be effective.
The benefits of minocycline demonstrated in the KO
mouse model prompted studies to investigate the effects
of minocycline in individuals with FXS. Utari et al
reported a survey of caregivers of children and adults
with FXS who were treated with minocycline clinically
for at least 2 weeks. Side effects were seen in 39.6% and
caregivers reported improvements in language, atten-
tion, social communication, and/or anxiety in approxi-
mately 70%.21 Paribello et al conducted an open-label
add-on trial of minocycline in individuals with FXS aged
13 years to 32 years. Minocycline treatment, well toler-
ated in this study, was associated with improvements in
behavior.22 The results of these studies have stimulated
a larger randomized, double-blind study reported here.
Objective/Hypothesis
Our objectives in this study were to determine the
behavioral effects of minocycline through a randomized,
double-blind, placebo-controlled crossover trial. Side
effects were closely monitored to assess the tolerability
of minocycline treatment. Our hypothesis was that
minocycline reduces problematic behaviors and that it is
safe for use in children with fragile X syndrome (FXS)
aged 3.5 years to 16 years for 3 months. We sought to
examine the role of age, gender, methylation status,
concomitant medication use, full scale intelligence quo-
tient (IQ), and severity of autistic behaviors on the
effects of minocycline in children with FXS.
METHODS
Study Design and Patients
This was a 6-month, single center, placebo-controlled,
double-blind crossover trial of minocycline treatment.
Participants received 3 months of treatment
with minocycline and 3 months of treatment with pla-
cebo. There was no washout between the 2 treatment
periods. Recruitment occurred from January 2010 to
June 2011, with the last participants completing the
study in December 2011. Results were disclosed at the
end of the trial for each patient. Patients were recruited
through the University of California Davis (UC Davis)
Medical Investigation of Neurodevelopmental Disorders
(MIND) Institute’s Fragile X Research and Treatment
Center and through the National Institute of Health’s
ClinicalTrials.gov registry.
Inclusion criteria included a diagnosis of fragile X syn-
drome (FXS) confirmed by FMR1 DNA testing, age
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between 3.5 years and 16 years and a stable regimen of
pharmacological treatment for at least 4 weeks before study
entry. Both male and female individuals were included.
Exclusion criteria included those who were pre-
viously treated with minocycline, plan to change phar-
macological intervention during the study, or had an
allergy to minocycline or tetracycline. There were no
exclusions for concomitant medication use.
Informed consent was obtained from caregivers before
participation and an assent was also obtained from
patients aged 12 years or older. Because of our vulnerable
subject population’s cognitive impairment, signatures
were not always obtained on the assent, but patients
were verbally briefed on the study description. The study
was approved by the UC Davis Institutional Review Board.
Randomization
Potential participants were assessed initially by tele-
phone with a screening questionnaire for inclusion and
exclusion criteria. Participants who met eligibility crite-
ria were scheduled for a baseline visit. After clinicians
determined a participant was eligible, randomization was
done by the UC Davis Medical Center Investigational
Drug Service based on order of receipt of study medi-
cation prescription. The random allocation sequence to
3 months of minocycline or placebo first was generated
via an online randomization program. No block ran-
domization was done. All study personnel, investigators,
and participants were blinded to treatment assigned until
completion of the trial period.
Intervention
Study medication consisted of identical appearing
capsules. The placebo contained the same inactive
ingredient as the minocycline capsules, methylcellulose.
Medication dosage was assigned based on weight, with
patients weighing up to 25 kg receiving 25 mg once daily,
those weighing between 25 kg and 45 kg receiving 50 mg
once daily, and those weighing .45 kg receiving 100 mg
once daily. Patients were advised to avoid dairy products
at least 30 minutes before and after taking study medica-
tion because of the possibility of minocycline chelating
with calcium, thus decreasing absorption. Participants
who were not able to swallow the capsules were allowed
to mix the capsule contents with nondairy food. After
patients were treated for 3 months with either minocy-
cline or placebo, they were crossed over and treated for
the following 3 months with the alternate therapy.
Assessments, Follow-Up, and Dose Monitoring
At baseline before the first treatment period, each
patient underwent standardized cognitive testing as
appropriate for age and expressive language level. Testing
was administered by a licensed psychologist or psycho-
metrist with experience testing individuals with fragile
X syndrome (FXS). Measures used were the Stanford Binet
5th Edition,23 Wechsler Abbreviated Scale for Intelligence,24
Mullen Scales of Early Learning,25 or the Leiter-Revised.26 An
Autism Diagnostic Observation Schedule (ADOS), and
Diagnostic and Statistical Manual of Mental Disorders, Text
Revision IV, diagnostic criteria were used to evaluate par-
ticipants for an autism spectrum disorder (ASD), which was
determined by clinician consensus.
At all visits, patients had a medical evaluation, which
included a detailed medical history, therapeutic inter-
vention review, medication review, side effects checklist,
and physical examination. The physicians discussed
potential side effects with caregivers and patients
including but not limited to the possibility of discolor-
ation of the teeth, particularly in those aged younger
than 8 years, gastrointestinal problems, increased sun
sensitivity, idiopathic intracranial hypertension, and
a drug-induced lupus-like reaction.
Primary and secondary outcome measures were per-
formed at baseline, repeated after 3 months at the end of
the patients’ first treatment arm, and then at 6 months
after the second arm. The primary outcome measures were
the Clinical Global Impressions Scale—Improvement
(CGI-I) and the Visual Analog Scale (VAS) for severity
of target behaviors for the most significant symptoms
that caregivers wanted to see improve (VAS1, severity of
target behavior 1). The CGI-I uses history from primary
caregivers and incorporates it into a 7-step clinical rating
for follow-up throughout treatment, from 1 “very much
improved” to 7 “very much worse.” A VAS is used to
represent a caregiver’s assessment of given behaviors,
which were chosen by the parents. Caregivers marked
a 10-cm horizontal line representing a visual continuum
of each behavior from “worst behavior” to “behavior
not a problem.” Visual analog scales have been used in
multiple prior studies to evaluate conditions such as
anxiety, depression, and quality of life.27–29
Secondary outcome measures were the VAS for sever-
ity of target symptoms rated second and third by the
parents (VAS2 and VAS3, severity of target behavior 2 and
3, respectively), Aberrant Behavior Checklist Community
Edition (ABC-C) composite score and subscales and sub-
scales that have been validated for the FXS population, the
Expressive Vocabulary Test Second Edition (EVT-2), and
Vineland Adaptive Behavior Scale (VABS)-II. The original
and revised versions of the ABC-C were used to quantify
the severity of a patient’s behaviors.30,31 The EVT-2
assesses language development through a participant’s
1-word synonym response to visual stimuli.32 The VABS-II
was used to assess adaptive skills.33
Along with participants being followed up with clinic
visits every 3 months for up to 6 months, phone calls
took place throughout the study (on days 7, 30, 60, 120,
150, and 180) to review concomitant medications and
list of questions regarding common side effects seen
with minocycline.
Molecular Measures
A blood sample for FMR1molecular measures, including
CGG repeat size, and methylation status was obtained from
each participant or results were provided by caregivers.
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Southern Blot and polymerase chain reaction-based geno-
typing were performed as previously described.34
Statistical Analysis
The model to assess efficacy was a linear mixed-effect
(LME) model for repeated measures in a minocycline/
placebo, 2-period cross-over trial. The model terms
included treatment, period, and baseline measurement if
available. Estimation was based on restricted maximum
likelihood and test denominator degrees of freedom was
based on the Kenward-Roger approximation. A model
including the sequence factor was used to check for
a carryover effect. Analysis of secondary measures follows
the same approach. In ad hoc analysis, the LME models
include baseline covariates to examine their effects,
including concomitant medication use, methylation status
(full or partial), full scale IQ score, and Autism Diagnostic
Observation Schedule (ADOS) total score, gender and age
group (,8 or $8 years of age). In ad hoc analysis (not
planned a priori) of symptom or behaviors described in
the 3 Visual Analog Scale (VAS) symptoms provided by
caregivers, we categorized the symptoms into anxiety/
mood symptoms, language-related symptoms, attention-
deficit hyperactivity disorder (ADHD)/impulsive symp-
toms, or other category. For example, for anxiety/mood,
we defined a combined symptom-specific VAS score as
the average of the individual VAS scores for those spe-
cific behaviors/symptoms. Similarly, combined VAS scores
for language-related symptoms, ADHD/impulsive symp-
toms or other category were determined. Comparison of
baseline and demographic variables between treatment
sequences were based on the t test and Fisher’s exact test
for continuous and categorical variables, respectively.
Adverse events (AEs) were summarized by type and
severity and compared using the generalized equation
estimation approach, and conclusions were the same
based on Fisher’s exact test. All tests were at level .05, and
analyses were implemented in SAS version 9.2.
The study was designed to achieve 85% power to
detect a treatment effect size of 0.55 at level alpha 5
.025 in a crossover design. The required sample size is




Sixty-nine subjects were assessed for eligibility, 66 of
which were randomized into the 2 treatment arms
(Fig. 1). Fifty-five subjects (83.3%) completed at least the
first period and were included in the intention-to-treat
Figure 1. CONSORT diagram.
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analysis. The demographic characteristics of these 55
subjects are shown in Table 1. There was no signifi-
cant difference between the 2 treatment sequences
(minocycline-placebo or placebo-minocycline) for baseline
and demographic variables. Forty-eight (72.7%) subjects
completed the second period. The majority of subjects in
both treatment sequences were boys, race white, and
average age of 9.0 years (minocycline-placebo) and
9.4 years (placebo-minocycline).
Primary Outcome Measures
The primary outcome measures are Clinical Global
Impressions Scale—Improvement (CGI-I) and Visual Ana-
log Scale (VAS) 1 score (severity of target behavior 1).
Minocycline showed statistically significant improvement
in CGI-I (2.49 6 0.13) compared with placebo (2.97 6
0.13; p 5 .0173); however, there was no difference
between treatment groups with respect to VAS1
(p 5 .67). See Table 2 (items 1 and 2a). Although statis-
tically significant, the CGI-I improvement (average of 0.5
points) was modest. The average VAS scores were rated as
more improved on minocycline than placebo, but the
difference was not significant. The largest improvement
trend was for the VAS2 score (severity for target behavior
2) (minocycline: 4.91 cm 6 0.31 cm, placebo: 4.16 cm 6
0.29 cm; p 5 .0607), a secondary measure.
Ad Hoc Analysis of VAS by Behavior Category
We performed an ad hoc analysis (not planned
a priori) of Visual Analog Scale (VAS) scores 1 to 3 by
behavior category, as detailed in the “Statistical
Analysis” section; see Table 1—item 2b. When the
VAS behaviors were grouped by behavior
category, minocycline was associated with a signifi-
cantly greater improvement in anxiety and mood-re-
lated behaviors (minocycline: 5.26 cm 6 0.46 cm,
placebo 4.05 cm 6 0.46 cm; p 5 .0488). Greater im-
provement was observed also for the “other” category,
which included being organized, potty training,
self-calming/self soothing, verbal initiation for play,
chewing objects, overstuffing, scratching stomach,
belching, running away, noncompliance/defiance, and self
injury. No significant carryover effects were observed from
the first treatment period to the next.
Secondary Outcome Measures
We did not observe any significant treatment effect
with respect to secondary measures, which included
the Aberrant Behavior Checklist Community Edition
(ABC-C), fragile X specific ABC-C, Vineland Adaptive
Behavior Scale (VABS)-II, Expressive Vocabulary Test




pN Mean SD N Mean SD
Age 28 9.01 3.76 27 9.40 3.39 .69
Full Scale IQ Standard Score 20 58.75 20.72 21 52.24 11.03 .22
ADOS Total Score 28 9.86 5.58 27 9.67 5.41 .90
N Percent N Percent p
Age group
Age , 8 yr 13 46 11 41 .79
Age $ 88 yr 15 54 16 59
Gender
Female 5 18 3 11 .70
Male 23 82 24 89
Race
Asian 2 7 4 15 .88
Black/African American 1 4 1 4
White 23 82 20 74
Other 2 7 2 7
Concomitant Medication
No 7 25 11 41 .26
Yes 21 75 16 59
Methylation
Full 14 61 14 67 .76
Partial 9 39 7 33
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Baseline Variable Effects
Additional ad hoc analyses explored effects of base-
line variables. Baseline concomitant medication use,
methylation status (full or partial), full scale IQ score, and
Autism Diagnostic Observation Schedule (ADOS) total
score were not significant in models of treatment dif-
ferences. Covariates gender and age group (,8 or $8
years of age) were significant in models for Visual Analog
Scale (VAS) target behavior 2 only, and trends of treat-
ment effects reported for primary analysis above were
similar (p 5 .0345 and .0458, respectively).
Safety and Tolerability of Minocycline
There were 144 adverse events (AEs) reported for 54
subjects (81.8%). Table 3 summarizes the types of AEs.
The majority of adverse events were rated as mild
(94.4%). There was no significant difference between
minocycline and placebo with regard to intensity,
relationship to study medication, resolution, and catego-
ries of adverse events. The most common adverse events
noted were gastrointestinal symptoms including loose
stools and decrease in appetite. There was one adverse
event rated as “serious,” which was a seizure, and when
the patient was unblinded, this occurred during the pla-
cebo arm. Most side effects resolved. Of note, brown and
yellow tooth discolorations were reported during
the minocycline trial period for 5 patients. However, most
of these discolorations resolved, and their significance is
unclear as the tooth staining associated with tetracyclines
is typically permanent.
DISCUSSION
This study is the first double-blind crossover study
of minocycline as a targeted treatment in fragile X
syndrome (FXS). Prior open-label studies have shown
benefits, and our controlled trial showed modest global
benefits, but there was also a placebo effect seen. This
study focused on a younger age range than the study by
Paribello et al22 and provides important evidence for the
safety of minocycline in the 3.5-year to 15.5-year age
range of children with FXS over a 3-month period. Most
adverse events (AEs) were mild and no severe AEs
occurred with minocycline treatment. However, a con-
cerning long-term side effect of minocycline is graying of
the permanent teeth, and this study did not last long
enough to assess this in patients who have not had
eruption of permanent teeth. It is likely that most will
have graying of their permanent teeth and caregivers
should be counseled about this. It does not appear that
gender, baseline IQ, severity of autism spectrum disorder
(ASD)-associated behavior as measured on the Autism
Diagnostic Observation Schedule (ADOS), concomitant
medication use, or methylation status are associated with
benefits seen with minocycline treatment.
This study is important because minocycline is a tar-
geted treatment for FXS that is currently available by
prescription, whereas other targeted treatments for FXS
including the mGluR5 negative modulators are not.
Minocycline has numerous biological effects aside
from its effects on MMP9 and has been studied as
a neuroprotective agent in diseases such as Huntington’s
disease and multiple sclerosis.35,36 There are several
mechanisms by which minocycline has been theorized to
exert its neuroprotective effects including anti-in-
flammatory effects by inhibiting microglial activation, de-
creasing caspase activity and through antiapoptotic
properties19,37 (Fig. 2). It is unclear whether these
additional neurobiological effects may be beneficial for
those with FXS and whether the positive outcome
reported here is because of changes in MMP9 levels or
additional mechanisms, which require further study.
Study limitations include the short treatment period of
only 3 months, as the effects of minocycline may take
longer to reach full effect. There was no formal wash out
period in the design of the study as there were 3 months in
Table 2. Primary Outcome Measures and Ad-Hoc Visual Analog Scale (VAS) Analysis
Baseline Minocycline Placebo
pN Mean SE LSmean SE LSmean SE
1. Clinical Global Impression—Improvement Scale* 55 — — 2.49 0.13 2.97 0.13 .02
2a. VAS Categorized by Severity
Visual Analog: Severity of Target Behavior 1* 55 2.28 0.21 4.60 0.31 4.44 0.30 .67
Visual Analog: Severity of Target Behavior 2 55 2.62 0.23 4.91 0.31 4.16 0.29 .06
Visual Analog: Severity of Target Behavior 3 50 2.80 0.27 4.88 0.36 4.13 0.35 .10
2b. VAS Categorized by Behavior (Ad-Hoc)
VAS Behavior Category
Aggression/ADHD 46 2.38 0.20 4.49 0.32 4.26 0.32 .53
Anxiety/Mood 26 2.47 0.25 5.26 0.46 4.05 0.46 .05
Language/Cognition 37 2.58 0.30 4.99 0.37 4.67 0.34 .51
Other 12 3.49 0.66 5.84 0.54 3.41 0.54 .009
ADHD, attention-deficit hyperactivity disorder; LSmean, least squares mean; SE, standard error. *Primary outcome measures, adjusted significance level is .025.
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between the 2 treatment arms, and it was felt that this
would be enough time for the minocycline to be
metabolized from the participant’s system. Carryover
effects are, therefore, possible because the synaptic struc-
tural effects of minocycline may persist; this is one limita-
tion of the study. However, the half-life of minocycline is
only 15.5 hours and we did not observe a statistically sig-
nificant carryover effect. It is still unknown whether and
how long minocycline may exert beneficial effects once it
is discontinued. Minocycline dosing was weight-based, but
for optimal effects in FXS, the dosage may have been too
low. Longer trials are needed to address long-term benefits
and side effects. We did not observe significant improve-
ment with minocycline treatment over placebo on any of
the secondary measures, which may have provided a bet-
ter indication regarding specific areas of functioning that
were responsive to the treatment. An important weakness
of the study design is that subjects were unblinded at the
time that they completed the study as opposed to the
conclusion of the study. This was done for the benefit of
the families who wanted to continue on minocycline
treatment if it was beneficial to the child. Furthermore,
Table 3. Characteristics of Adverse Events During Minocycline and Placebo Periods
Minocycline Placebo
pN % N %
Intensity
Mild 67 94 69 95 .63
Moderate 4 6 3 4
Severe 0 0 1 1
Drug related
Probably related 2 3 0 0 .93
Possibly related 66 93 66 90
Not related 3 4 7 10
Resolved
No 5 7 1 1 .14
Yes 66 93 72 99
Adverse Event Type .38
Diarrhea/loose stools 15 21 15 21
Gastrointestinal upset/vomiting/loss of appetite 9 13 15 21
Skin rash/itching/swelling 12 17 7 10
Fever/chills/URI symptoms/sore throat 6 8 11 15
Ear infection 0 0 2 3
Fungal skin infection 1 1 1 1
Headache 4 6 5 7
Sunburn/sun sensitivity 4 6 1 1
Drowsiness 2 3 3 4
Increased agitation, aggression, tantrums, uncooperative, irritability 1 1 4 5
Blue-gray/gray hue to teeth or other tissues 3 4 1 1
Yellowish teeth 3 4 0 0
Brownish teeth 2 3 0 0
Dark-colored urine/Changes in urination 1 1 2 3
Increased appetite 2 3 1 1
Trouble sleeping 2 3 0 0
Seizure/staring spell 1 1 1 1
Dizziness/unsteadiness 0 0 1 1
Masturbation 1 1 0 0
Right leg pain 1 1 0 0
Constipation 1 1 1 1
Sneezing, itchy eyes 0 0 1 1
Pressure equalizing tubes removed 0 0 1 1
URI, upper respiratory infection
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a preliminary efficacy analysis based on subjects who have
completed the study was performed showing poten-
tial efficacy. These 2 aspects pose potential bias to the
final reported efficacy results. Another weakness is that
drug-related side effects have the potential to unblind both
subjects and investigators; for minocycline, these include
teeth graying and photosensitivity. However, there was no
significant difference in these effects or any other side
effects between the 2 study groups. We had only 1 episode
of unblinding because of a serious AE (a seizure) and the
patient was on placebo. A similar number of patients
completed the trial in each arm (Fig. 1). Finally, the
designed study power was 85%. This was not fully ach-
ieved potentially because the number of enrolled patients
was about 10% below planned recruitment and not all
subjects completed both study periods.
CONCLUSIONS
Minocycline treatment for 3 months in children with
fragile X syndrome (FXS) was associated with greater ben-
efits in global functioning when compared with placebo,
although the clinical improvement was modest. Treatment
with minocycline for 3 months was safe as almost all side
effects were mild and no different than on placebo. Further
studies including long-term follow-up of individuals with
FXS treated with minocycline are warranted with a careful
assessment of effects on dentition and the immune system.
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